{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:14:41Z","timestamp":1791357281942,"version":"4.3.1"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,8,2]],"date-time":"2019-08-02T00:00:00Z","timestamp":1564704000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,8,2]],"date-time":"2019-08-02T00:00:00Z","timestamp":1564704000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The identification of biomarkers of response might speed drug development and set the premises to assist clinical practice in psychiatry. In this work, we evaluated a panel of peripheral biomarkers (including IL-6, IL-10, TNF-\u03b1, TNFRII, BDNF, CRP, MMP9 and PAI1) in depressed patients receiving paroxetine, venlafaxine, or placebo. Samples were obtained from two randomised placebo-controlled studies evaluating the efficacy and tolerability of a novel drug candidate, using either paroxetine or venlafaxine as active comparators. In both studies, the biomarker candidates were analysed in plasma collected at randomization and after 10 weeks of treatment with either placebo or active comparator (for a total of 106 and 108 subjects in the paroxetine and venlafaxine study, respectively). Data were obtained by multiplexing sandwich-ELISA system. Data were subjected to statistical analysis to assess their correlation with baseline severity and with response outcome. Increases in biomarker levels were correlated with reduction in depression severity for TNF-\u03b1, IL-6 IL-10 and CRP. Response to paroxetine treatment correlated with baseline IL-10, IL-6 and TNF-\u03b1 levels, with the strongest signal being observed in males. In the venlafaxine study, a correlation was observed only between CRP level at randomisation and response, suggesting differences between the two active treatments and the two studies. Our investigations suggest that a combination of pro- and anti-inflammatory cytokines may predict response outcome in patients treated with paroxetine. The potential for IL-10, IL-6 and TNF-\u03b1 as response biomarkers for a wider range of antidepressants warrants further investigations in clinical trials with other monoamine reuptake inhibitors.<\/jats:p>","DOI":"10.1038\/s41398-019-0521-7","type":"journal-article","created":{"date-parts":[[2019,8,2]],"date-time":"2019-08-02T07:10:32Z","timestamp":1564729832000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":83,"title":["Biomarkers for response in major depression: comparing paroxetine and venlafaxine from two randomised placebo-controlled clinical studies"],"prefix":"10.1038","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9335-3312","authenticated-orcid":false,"given":"Lucia","family":"Carboni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis J.","family":"McCarthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Delafont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Filosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Ivanchenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emiliangelo","family":"Ratti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan M.","family":"Learned","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7436-6919","authenticated-orcid":false,"given":"Enrico","family":"Domenici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,2]]},"reference":[{"key":"521_CR1","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1517\/17530059.1.2.235","volume":"1","author":"E Domenici","year":"2007","unstructured":"Domenici, E. & Muglia, P. The search for peripheral disease markers in psychiatry by genomic and proteomic approaches. Expert Opin. Med Diagn. 1, 235\u2013251 (2007).","journal-title":"Expert Opin. Med Diagn."},{"key":"521_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jad.2017.07.001","volume":"233","author":"BS Gadad","year":"2018","unstructured":"Gadad, B. S. et al. Peripheral biomarkers of major depression and antidepressant treatment response: Current knowledge and future outlooks. J. Affect Disord. 233, 3\u201314 (2018).","journal-title":"J. Affect Disord."},{"key":"521_CR3","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1080\/14737159.2018.1470927","volume":"18","author":"C Mora","year":"2018","unstructured":"Mora, C., Zonca, V., Riva, M. A. & Cattaneo, A. Blood biomarkers and treatment response in major depression. Expert Rev. Mol. Diagn. 18, 513\u2013529 (2018).","journal-title":"Expert Rev. Mol. Diagn."},{"key":"521_CR4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0030442","volume":"3","author":"CD Mathers","year":"2006","unstructured":"Mathers, C. D. & Loncar, D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 3, e442 (2006).","journal-title":"PLoS Med"},{"key":"521_CR5","doi-asserted-by":"crossref","unstructured":"Domenici, E, Muglia, P. & Merlo-Pich, E. Hunting for peripheral biomarkers to support drug development in psychiatry. in Biomarkers for Psychiatric Disorders. 405\u2013426 (Springer US, Boston, MA, 2008).","DOI":"10.1007\/978-0-387-79251-4_16"},{"key":"521_CR6","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1038\/nn.4113","volume":"18","author":"GE Hodes","year":"2015","unstructured":"Hodes, G. E., Kana, V., Menard, C., Merad, M. & Russo, S. J. Neuroimmune mechanisms of depression. Nat. Neurosci. 18, 1386\u20131393 (2015).","journal-title":"Nat. Neurosci."},{"key":"521_CR7","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/nri.2015.5","volume":"16","author":"AH Miller","year":"2015","unstructured":"Miller, A. H. & Raison, C. L. The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat. Rev. Immunol. 16, 22\u201334 (2015).","journal-title":"Nat. Rev. Immunol."},{"key":"521_CR8","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1080\/07853890310004075","volume":"35","author":"H Anisman","year":"2003","unstructured":"Anisman, H. & Merali, Z. Cytokines, stress and depressive illness: brain-immune interactions. Ann. Med 35, 2\u201311 (2003).","journal-title":"Ann. Med"},{"key":"521_CR9","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/mp.2016.167","volume":"23","author":"N Kappelmann","year":"2018","unstructured":"Kappelmann, N., Lewis, G., Dantzer, R., Jones, P. B. & Khandaker, G. M. Antidepressant activity of anti-cytokine treatment: a systematic review and meta-analysis of clinical trials of chronic inflammatory conditions. Mol. Psychiatry 23, 335\u2013343 (2018).","journal-title":"Mol. Psychiatry"},{"key":"521_CR10","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1001\/2013.jamapsychiatry.4","volume":"70","author":"CL Raison","year":"2013","unstructured":"Raison, C. L. et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression. JAMA Psychiatry 70, 31 (2013).","journal-title":"JAMA Psychiatry"},{"key":"521_CR11","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1111\/acps.12698","volume":"135","author":"CA K\u00f6hler","year":"2017","unstructured":"K\u00f6hler, C. A. et al. Peripheral cytokine and chemokine alterations in depression: a meta-analysis of 82 studies. Acta Psychiatr. Scand. 135, 373\u2013387 (2017).","journal-title":"Acta Psychiatr. Scand."},{"key":"521_CR12","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.jad.2013.06.004","volume":"150","author":"V Valkanova","year":"2013","unstructured":"Valkanova, V., Ebmeier, K. P. & Allan, C. L. CRP, IL-6 and depression: A systematic review and meta-analysis of longitudinal studies. J. Affect Disord. 150, 736\u2013744 (2013).","journal-title":"J. Affect Disord."},{"key":"521_CR13","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.bbi.2015.06.001","volume":"49","author":"R Haapakoski","year":"2015","unstructured":"Haapakoski, R., Mathieu, J., Ebmeier, K. P., Alenius, H. & Kivim\u00e4ki, M. Cumulative meta-analysis of interleukins 6 and 1\u03b2, tumour necrosis factor \u03b1 and C-reactive protein in patients with major depressive disorder. Brain Behav. Immun. 49, 206\u2013215 (2015).","journal-title":"Brain Behav. Immun."},{"key":"521_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pnpbp.2016.02.006","volume":"68","author":"HA Eyre","year":"2016","unstructured":"Eyre, H. A. et al. A meta-analysis of chemokines in major depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 68, 1\u20138 (2016).","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"521_CR15","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.biopsych.2009.09.033","volume":"67","author":"Y Dowlati","year":"2010","unstructured":"Dowlati, Y. et al. A meta-analysis of cytokines in major depression. Biol. Psychiatry 67, 446\u2013457 (2010).","journal-title":"Biol. Psychiatry"},{"key":"521_CR16","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.pnpbp.2017.04.026","volume":"80","author":"M Wi\u0119d\u0142ocha","year":"2018","unstructured":"Wi\u0119d\u0142ocha, M. et al. Effect of antidepressant treatment on peripheral inflammation markers \u2013 A meta-analysis. Prog. Neuropsychopharmacol. Biol. Psychiatry 80, 217\u2013226 (2018).","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"521_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jpsychires.2017.05.012","volume":"94","author":"BS Gadad","year":"2017","unstructured":"Gadad, B. S., Jha, M. K., Grannemann, B. D., Mayes, T. L. & Trivedi, M. H. Proteomics profiling reveals inflammatory biomarkers of antidepressant treatment response: findings from the CO-MED trial. J. Psychiatr. Res 94, 1\u20136 (2017).","journal-title":"J. Psychiatr. Res"},{"key":"521_CR18","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1016\/j.euroneuro.2015.06.007","volume":"25","author":"R Strawbridge","year":"2015","unstructured":"Strawbridge, R. et al. Inflammation and clinical response to treatment in depression: a meta-analysis. Eur. Neuropsychopharmacol. 25, 1532\u20131543 (2015).","journal-title":"Eur. Neuropsychopharmacol."},{"key":"521_CR19","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1038\/mp.2016.3","volume":"21","author":"DR Goldsmith","year":"2016","unstructured":"Goldsmith, D. R., Rapaport, M. H. & Miller, B. J. A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression. Mol. Psychiatry 21, 1696\u20131709 (2016).","journal-title":"Mol. Psychiatry"},{"key":"521_CR20","first-page":"4195","volume":"55","author":"CA K\u00f6hler","year":"2018","unstructured":"K\u00f6hler, C. A. et al. Peripheral alterations in cytokine and chemokine levels after antidepressant drug treatment for major depressive disorder: systematic review and meta-analysis. Mol. Neurobiol. 55, 4195\u20134206 (2018).","journal-title":"Mol. Neurobiol."},{"key":"521_CR21","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jad.2018.12.037","volume":"246","author":"R Strawbridge","year":"2019","unstructured":"Strawbridge, R. et al. Inflammatory profiles of severe treatment-resistant depression. J. Affect Disord. 246, 42\u201351 (2019).","journal-title":"J. Affect Disord."},{"key":"521_CR22","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/S0893-133X(99)00134-7","volume":"22","author":"S Lanquillon","year":"2000","unstructured":"Lanquillon, S., Krieg, J.-C., Bening-Abu-Shach, U. & Vedder, H. Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology 22, 370\u2013379 (2000).","journal-title":"Neuropsychopharmacology"},{"key":"521_CR23","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.psyneuen.2018.05.026","volume":"95","author":"E Haroon","year":"2018","unstructured":"Haroon, E. et al. Antidepressant treatment resistance is associated with increased inflammatory markers in patients with major depressive disorder. Psychoneuroendocrinology 95, 43\u201349 (2018).","journal-title":"Psychoneuroendocrinology"},{"key":"521_CR24","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1016\/j.euroneuro.2012.09.009","volume":"23","author":"TR Powell","year":"2013","unstructured":"Powell, T. R. et al. Tumor necrosis factor and its targets in the inflammatory cytokine pathway are identified as putative transcriptomic biomarkers for escitalopram response. Eur. Neuropsychopharmacol. 23, 1105\u20131114 (2013).","journal-title":"Eur. Neuropsychopharmacol."},{"key":"521_CR25","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.pnpbp.2007.09.015","volume":"32","author":"T Eller","year":"2008","unstructured":"Eller, T., Vasar, V., Shlik, J. & Maron, E. Pro-inflammatory cytokines and treatment response to escitalopram in major depressive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 32, 445\u2013450 (2008).","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"521_CR26","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.jad.2018.04.037","volume":"235","author":"MH Huang","year":"2018","unstructured":"Huang, M. H. et al. Elevated tumor necrosis factor-alpha receptor subtype 1 and the association with abnormal brain function in treatment-resistant depression. J. Affect Disord. 235, 250\u2013256 (2018).","journal-title":"J. Affect Disord."},{"key":"521_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2017.31","volume":"7","author":"DD Kiraly","year":"2017","unstructured":"Kiraly, D. D. et al. Altered peripheral immune profiles in treatment-resistant depression: response to ketamine and prediction of treatment outcome. Transl. Psychiatry 7, e1065 (2017).","journal-title":"Transl. Psychiatry"},{"key":"521_CR28","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.neubiorev.2017.10.001","volume":"83","author":"JV Pinto","year":"2017","unstructured":"Pinto, J. V., Moulin, T. C. & Amaral, O. B. On the transdiagnostic nature of peripheral biomarkers in major psychiatric disorders: a systematic review. Neurosci. Biobehav Rev. 83, 97\u2013108 (2017).","journal-title":"Neurosci. Biobehav Rev."},{"key":"521_CR29","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1177\/0269881111424931","volume":"26","author":"S Learned","year":"2012","unstructured":"Learned, S. et al. Efficacy, safety, and tolerability of a triple reuptake inhibitor GSK372475 in the treatment of patients with major depressive disorder: two randomized, placebo- and active-controlled clinical trials. J. Psychopharmacol. 26, 653\u2013662 (2012).","journal-title":"J. Psychopharmacol."},{"key":"521_CR30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0009166","volume":"5","author":"E Domenici","year":"2010","unstructured":"Domenici, E. et al. Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case-control collections. PLoS ONE 5, e9166 (2010).","journal-title":"PLoS ONE"},{"key":"521_CR31","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1146\/annurev.immunol.19.1.683","volume":"19","author":"KW Moore","year":"2001","unstructured":"Moore, K. W., de Waal Malefyt, R., Coffman, R. L. & O\u2019Garra, A. Interleukin-10 and the interleukin-10 receptor. Annu Rev. Immunol. 19, 683\u2013765 (2001).","journal-title":"Annu Rev. Immunol."},{"key":"521_CR32","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1111\/j.1600-065X.2008.00706.x","volume":"226","author":"DM Mosser","year":"2008","unstructured":"Mosser, D. M. & Zhang, X. Interleukin-10: new perspectives on an old cytokine. Immunol. Rev. 226, 205\u2013218 (2008).","journal-title":"Immunol. Rev."},{"key":"521_CR33","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1590\/1516-4446-2014-1452","volume":"37","author":"M Gazal","year":"2015","unstructured":"Gazal, M. et al. Association of interleukin-10 levels with age of onset and duration of illness in patients with major depressive disorder. Rev. Bras. Psiquiatr 37, 296\u2013302 (2015).","journal-title":"Rev. Bras. Psiquiatr"},{"key":"521_CR34","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/S0165-0327(02)00002-2","volume":"74","author":"G Parker","year":"2003","unstructured":"Parker, G., Roy, K., Hadzi-Pavlovic, D., Mitchell, P. & Wilhelm, K. Distinguishing early and late onset non-melancholic unipolar depression. J. Affect Disord. 74, 131\u2013138 (2003).","journal-title":"J. Affect Disord."},{"key":"521_CR35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0058488","volume":"8","author":"JL Voorhees","year":"2013","unstructured":"Voorhees, J. L. et al. Prolonged restraint stress increases IL-6, reduces IL-10, and causes persistent depressive-like behavior that is reversed by recombinant IL-10. PLoS ONE 8, e58488 (2013).","journal-title":"PLoS ONE"},{"key":"521_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-015-0416-3","volume":"12","author":"A Han","year":"2015","unstructured":"Han, A. et al. IL-4\/10 prevents stress vulnerability following imipramine discontinuation. J. Neuroinflamm. 12, 197 (2015).","journal-title":"J. Neuroinflamm."},{"key":"521_CR37","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jpsychires.2008.02.004","volume":"43","author":"AR Mesquita","year":"2008","unstructured":"Mesquita, A. R. et al. IL-10 modulates depressive-like behavior. J. Psychiatr. Res 43, 89\u201397 (2008).","journal-title":"J. Psychiatr. Res"},{"key":"521_CR38","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.neuron.2018.08.001","volume":"99","author":"SA Syed","year":"2018","unstructured":"Syed, S. A. et al. Defective inflammatory pathways in never-treated depressed patients are associated with poor treatment response. Neuron 99, 914\u2013924.e3 (2018).","journal-title":"Neuron"},{"key":"521_CR39","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.psychres.2016.02.052","volume":"239","author":"FM Schmidt","year":"2016","unstructured":"Schmidt, F. M. et al. Pro- and anti-inflammatory cytokines, but not CRP, are inversely correlated with severity and symptoms of major depression. Psychiatry Res 239, 85\u201391 (2016).","journal-title":"Psychiatry Res"},{"key":"521_CR40","doi-asserted-by":"publisher","DOI":"10.1002\/hup.2588","volume":"32","author":"N Fan","year":"2017","unstructured":"Fan, N., Luo, Y., Ou, Y. & He, H. Altered serum levels of TNF-\u03b1, IL-6, and IL-18 in depressive disorder patients. Hum. Psychopharmacol. Clin. Exp. 32, e2588 (2017).","journal-title":"Hum. Psychopharmacol. Clin. Exp."},{"key":"521_CR41","doi-asserted-by":"publisher","first-page":"437","DOI":"10.2147\/NDT.S123121","volume":"13","author":"R Yoshimura","year":"2017","unstructured":"Yoshimura, R. et al. Influence of fluvoxamine on plasma interleukin-6 or clinical improvement in patients with major depressive disorder. Neuropsychiatr. Dis. Treat. 13, 437\u2013441 (2017).","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"521_CR42","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.pnpbp.2007.03.004","volume":"31","author":"YK Kim","year":"2007","unstructured":"Kim, Y. K. et al. Cytokine imbalance in the pathophysiology of major depressive disorder. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 31, 1044\u20131053 (2007).","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"521_CR43","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.pnpbp.2009.03.020","volume":"33","author":"R Yoshimura","year":"2009","unstructured":"Yoshimura, R. et al. Higher plasma interleukin-6 (IL-6) level is associated with SSRI- or SNRI-refractory depression. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 33, 722\u2013726 (2009).","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"521_CR44","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1176\/appi.ajp.162.1.175","volume":"162","author":"AJ Thomas","year":"2005","unstructured":"Thomas, A. J. et al. Increase in interleukin-1beta in late-life depression. Am. J. Psychiatry 162, 175\u2013177 (2005).","journal-title":"Am. J. Psychiatry"},{"key":"521_CR45","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1007\/s12640-017-9835-5","volume":"33","author":"M Sowa-Ku\u0107ma","year":"2018","unstructured":"Sowa-Ku\u0107ma, M. et al. Lipid peroxidation and immune biomarkers are associated with major depression and its phenotypes, including treatment-resistant depression and melancholia. Neurotox. Res 33, 448\u2013460 (2018).","journal-title":"Neurotox. Res"},{"key":"521_CR46","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.psyneuen.2014.03.019","volume":"45","author":"J Dahl","year":"2014","unstructured":"Dahl, J. et al. The plasma levels of various cytokines are increased during ongoing depression and are reduced to normal levels after recovery. Psychoneuroendocrinology 45, 77\u201386 (2014).","journal-title":"Psychoneuroendocrinology"},{"key":"521_CR47","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.jpsychires.2006.05.013","volume":"41","author":"SM O\u2019Brien","year":"2007","unstructured":"O\u2019Brien, S. M., Scully, P., Fitzgerald, P., Scott, L. V. & Dinan, T. G. Plasma cytokine profiles in depressed patients who fail to respond to selective serotonin reuptake inhibitor therapy. J. Psychiatr. Res 41, 326\u2013331 (2007).","journal-title":"J. Psychiatr. Res"},{"key":"521_CR48","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.bbi.2011.07.239","volume":"26","author":"HH Chang","year":"2012","unstructured":"Chang, H. H. et al. Treatment response and cognitive impairment in major depression: association with C-reactive protein. Brain Behav. Immun. 26, 90\u201395 (2012).","journal-title":"Brain Behav. Immun."},{"key":"521_CR49","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1017\/S0033291712000128","volume":"42","author":"SA Hiles","year":"2012","unstructured":"Hiles, S. A., Baker, A. L., de Malmanche, T. & Attia, J. Interleukin-6, C-reactive protein and interleukin-10 after antidepressant treatment in people with depression: a meta-analysis. Psychol. Med 42, 2015\u20132026 (2012).","journal-title":"Psychol. Med"},{"key":"521_CR50","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1038\/npp.2011.132","volume":"36","author":"J Hannestad","year":"2011","unstructured":"Hannestad, J., DellaGioia, N. & Bloch, M. The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis. Neuropsychopharmacology 36, 2452\u20132459 (2011).","journal-title":"Neuropsychopharmacology"},{"key":"521_CR51","doi-asserted-by":"publisher","first-page":"97","DOI":"10.2174\/157015912800604542","volume":"10","author":"M Martino","year":"2012","unstructured":"Martino, M., Rocchi, G., Escelsior, A. & Fornaro, M. Immunomodulation mechanism of antidepressants: interactions between serotonin\/norepinephrine balance and Th1\/Th2 Balance. Curr. Neuropharmacol. 10, 97\u2013123 (2012).","journal-title":"Curr. Neuropharmacol."},{"key":"521_CR52","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/npp.2012.191","volume":"38","author":"A Cattaneo","year":"2013","unstructured":"Cattaneo, A. et al. Candidate genes expression profile associated with antidepressants response in the GENDEP Study: differentiating between baseline \u2018predictors\u2019 and longitudinal \u2018Targets\u2019. Neuropsychopharmacology 38, 377\u2013385 (2013).","journal-title":"Neuropsychopharmacology"},{"key":"521_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ijnp\/pyw045","volume":"19","author":"A Cattaneo","year":"2016","unstructured":"Cattaneo, A. et al. Absolute measurements of macrophage migration inhibitory factor and interleukin-1-\u03b2 mRNA levels accurately predict treatment response in depressed patients. Int J. Neuropsychopharmacol. 19, 1\u201310 (2016).","journal-title":"Int J. Neuropsychopharmacol."},{"key":"521_CR54","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.jad.2012.10.036","volume":"148","author":"LA Carvalho","year":"2013","unstructured":"Carvalho, L. A. et al. Lack of clinical therapeutic benefit of antidepressants is associated overall activation of the inflammatory system. J. Affect Disord. 148, 136\u2013140 (2013).","journal-title":"J. Affect Disord."},{"key":"521_CR55","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1002\/hup.2333","volume":"28","author":"R Yoshimura","year":"2013","unstructured":"Yoshimura, R. et al. Plasma levels of interleukin-6 and selective serotonin reuptake inhibitor response in patients with major depressive disorder. Hum. Psychopharmacol. Clin. Exp. 28, 466\u2013470 (2013).","journal-title":"Hum. Psychopharmacol. Clin. Exp."},{"key":"521_CR56","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1002\/hup.717","volume":"20","author":"AD Basterzi","year":"2005","unstructured":"Basterzi, A. D. et al. IL-6 levels decrease with SSRI treatment in patients with major depression. Hum. Psychopharmacol. 20, 473\u2013476 (2005).","journal-title":"Hum. Psychopharmacol."},{"key":"521_CR57","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1177\/0269881108091077","volume":"23","author":"T Eller","year":"2009","unstructured":"Eller, T., Vasar, V., Shlik, J. & Maron, E. Effects of bupropion augmentation on pro-inflammatory cytokines in escitalopram-resistant patients with major depressive disorder. J. Psychopharmacol. 23, 854\u2013858 (2009).","journal-title":"J. Psychopharmacol."},{"key":"521_CR58","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.jad.2012.08.007","volume":"145","author":"M Fornaro","year":"2013","unstructured":"Fornaro, M., Rocchi, G., Escelsior, A., Contini, P. & Martino, M. Might different cytokine trends in depressed patients receiving duloxetine indicate differential biological backgrounds. J. Affect Disord. 145, 300\u2013307 (2013).","journal-title":"J. Affect Disord."},{"key":"521_CR59","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.psyneuen.2017.10.009","volume":"87","author":"C-Y Chen","year":"2018","unstructured":"Chen, C.-Y. et al. Differences in immunomodulatory properties between venlafaxine and paroxetine in patients with major depressive disorder. Psychoneuroendocrinology 87, 108\u2013118 (2018).","journal-title":"Psychoneuroendocrinology"},{"key":"521_CR60","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.jpsychires.2016.08.020","volume":"83","author":"MK Chan","year":"2016","unstructured":"Chan, M. K. et al. Blood-based immune-endocrine biomarkers of treatment response in depression. J. Psychiatr. Res 83, 249\u2013259 (2016).","journal-title":"J. Psychiatr. Res"},{"key":"521_CR61","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1176\/appi.ajp.2014.14010094","volume":"171","author":"R Uher","year":"2014","unstructured":"Uher, R. et al. An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram and nortriptyline. Am. J. Psychiatry 171, 1278\u20131286 (2014).","journal-title":"Am. J. Psychiatry"},{"key":"521_CR62","doi-asserted-by":"publisher","DOI":"10.1007\/s11920-015-0618-5","volume":"17","author":"HM Derry","year":"2015","unstructured":"Derry, H. M., Padin, A. C., Kuo, J. L., Hughes, S. & Kiecolt-Glaser, J. K. Sex differences in depression: does inflammation play a role? Curr. Psychiatry Rep. 17, 78 (2015).","journal-title":"Curr. Psychiatry Rep."},{"key":"521_CR63","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/S0006-3223(02)01811-5","volume":"54","author":"BWJH Penninx","year":"2003","unstructured":"Penninx, B. W. J. H. et al. Inflammatory markers and depressed mood in older persons: results from the Health, Aging and Body Composition study. Biol. Psychiatry 54, 566\u2013572 (2003).","journal-title":"Biol. Psychiatry"},{"key":"521_CR64","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/S0022-3956(99)00021-7","volume":"33","author":"M Haack","year":"1999","unstructured":"Haack, M. et al. Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: effects of confounding factors and diagnosis. J. Psychiatr. Res 33, 407\u2013418 (1999).","journal-title":"J. Psychiatr. Res"},{"key":"521_CR65","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.jad.2005.07.008","volume":"88","author":"A-M Myint","year":"2005","unstructured":"Myint, A.-M., Leonard, B. E., Steinbusch, H. W. M. & Kim, Y.-K. Th1, Th2, and Th3 cytokine alterations in major depression. J. Affect Disord. 88, 167\u2013173 (2005).","journal-title":"J. Affect Disord."},{"key":"521_CR66","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.psychres.2007.12.004","volume":"167","author":"Y Ovaskainen","year":"2009","unstructured":"Ovaskainen, Y. et al. Depressive symptomatology is associated with decreased interleukin-1 beta and increased interleukin-1 receptor antagonist levels in males. Psychiatry Res 167, 73\u201379 (2009).","journal-title":"Psychiatry Res"},{"key":"521_CR67","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1097\/PSY.0b013e31819e333a","volume":"71","author":"M Elovainio","year":"2009","unstructured":"Elovainio, M. et al. Depression and C-reactive protein: population-based Health 2000 Study. Psychosom. Med 71, 423\u2013430 (2009).","journal-title":"Psychosom. Med"},{"key":"521_CR68","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1001\/archinte.164.9.1010","volume":"164","author":"DE Ford","year":"2004","unstructured":"Ford, D. E. & Erlinger, T. P. Depression and C-reactive protein in US adults: data from the Third National Health and Nutrition Examination Survey. Arch. Intern Med 164, 1010\u20131014 (2004).","journal-title":"Arch. Intern Med"},{"key":"521_CR69","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2012.8","volume":"2","author":"N Vogelzangs","year":"2012","unstructured":"Vogelzangs, N. et al. Association of depressive disorders, depression characteristics and antidepressant medication with inflammation. Transl. Psychiatry 2, e79 (2012).","journal-title":"Transl. Psychiatry"},{"key":"521_CR70","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.psychres.2015.06.036","volume":"229","author":"P Pallavi","year":"2015","unstructured":"Pallavi, P. et al. Serum cytokines and anxiety in adolescent depression patients: Gender effect. Psychiatry Res 229, 374\u2013380 (2015).","journal-title":"Psychiatry Res"},{"key":"521_CR71","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.physbeh.2017.11.009","volume":"184","author":"M Majd","year":"2018","unstructured":"Majd, M. et al. Distinct inflammatory response patterns are evident among men and women with higher depressive symptoms. Physiol. Behav. 184, 108\u2013115 (2018).","journal-title":"Physiol. Behav."},{"key":"521_CR72","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2012.112","volume":"2","author":"R Belzeaux","year":"2012","unstructured":"Belzeaux, R. et al. Responder and nonresponder patients exhibit different peripheral transcriptional signatures during major depressive episode. Transl. Psychiatry 2, e185 (2012).","journal-title":"Transl. Psychiatry"},{"key":"521_CR73","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2016.214","volume":"6","author":"A Cattaneo","year":"2016","unstructured":"Cattaneo, A., Cattane, N., Begni, V., Pariante, C. M. & Riva, M. A. The human BDNF gene: peripheral gene expression and protein levels as biomarkers for psychiatric disorders. Transl. Psychiatry 6, e958 (2016).","journal-title":"Transl. Psychiatry"},{"key":"521_CR74","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/ajmg.b.30272","volume":"141B","author":"PF Sullivan","year":"2006","unstructured":"Sullivan, P. F., Fan, C. & Perou, C. M. Evaluating the comparability of gene expression in blood and brain. Am. J. Med Genet B Neuropsychiatr. Genet 141B, 261\u2013268 (2006).","journal-title":"Am. J. Med Genet B Neuropsychiatr. Genet"}],"container-title":["Translational Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41398-019-0521-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-019-0521-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-019-0521-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T10:38:43Z","timestamp":1671187123000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41398-019-0521-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,2]]},"references-count":74,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["521"],"URL":"https:\/\/doi.org\/10.1038\/s41398-019-0521-7","relation":{},"ISSN":["2158-3188"],"issn-type":[{"value":"2158-3188","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,2]]},"assertion":[{"value":"2 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Lucia Carboni, Elena Ivanchenko, Bruno Delafont, Emiliangelo Ratti, Robert Alexander, Enrico Domenici and Susan Learned were employees of GSK at the time of the study. Enrico Domenici was an employee of F. Hoffmann-La Roche until 2015 and later served as a consultant to Roche and Pierre-Fabre in the area of genetic biomarkers. Emiliangelo Ratti and Robert Alexander are currently employees of Takeda; Susan Learned is an employee of Indivior; Elena Ivanchenko is an employee of Leadiant.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"182"}}